Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Clover Health Looks Primed to Go Out of This World

By Chris Markoch, InvestorPlace Contributor

I feel almost certain that CLOV stock is going to move higher in the short term. How much higher and how long it will last are anybody’s guess.

Don’t Count on a Covid-19 Boost for Vaxart

By Chris Markoch, InvestorPlace Contributor

VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day.

Airbnb is a Disruptive Company That is Overvalued

By Chris Markoch, InvestorPlace Contributor

After trading publicly for six months, ABNB stock is back to where it started. Investors may be realizing that the company uses tech, but is not a tech stock.

For ContextLogic, Growth Is More Than Just Wishful Thinking

By Chris Markoch, InvestorPlace Contributor

If you’re patient and have an appetite for risk, then WISH stock has upside that shouldn’t be ignored. Here's why.

Cardano Has a Robust, Encouraging Roadmap for Future Development

By Chris Markoch, InvestorPlace Contributor

Cardano gives investors tangible reasons to believe that ADA will be around for the long haul. And in an asset class where coins are sent “to the moon” on a lot less, those reasons may be enough to consider an investment. 

A Little Patience Could Go a Long Way For ZOM Stock

By Chris Markoch, InvestorPlace Contributor

ZOM stock is trading below $1 as investors are in a holding pattern as they wait for the company to report earnings in August.

Don’t Give Up on QuantumScape Just Yet

By Chris Markoch, InvestorPlace Contributor

QS stock looks overvalued and may have further to drop. However, a new hire indicates the company may have a better outlook later this year.

Hyliion Is Difficult to Judge Without Quantitative Metrics

By Chris Markoch, InvestorPlace Contributor

Hyliion CEO Thomas Healy advises employees to not let the HYLN stock price become their focus, but investors should remain cautious.

MicroVision Stock Is Still Overvalued Despite Bullish Sentiment

By Chris Markoch, InvestorPlace Contributor

Despite support from Reddit traders and the potential for explosive growth in its sector, there are signs that MVIS stock is overvalued.  

Canoo Stock Is Priced Low Enough to Be Worth a Second Look

By Chris Markoch, InvestorPlace Contributor

Canoo faces many hurdles, but also has many opportunities. With a range of outcomes possible for GOEV stock, the wise strategy is to hold.

Load More